MeiraGTx Holdings (FRA:328) Market Cap: €983.87 Mil (As of Jun. 28, 2026)


FRA:328 MeiraGTx Holdings PLC FRA:328
55 GF Score
Price €10.00
GF Value €19.70
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MeiraGTx Holdings Market Cap?

MeiraGTx Holdings FRA:328 -0.99% 55 Market Cap is €983.87 Mil as of Jun. 28, 2026. GuruFocus rates FRA:328 with a GF Score™ of 55/100 and a GF Value™ of €19.70 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,429 Biotechnology companies, MeiraGTx Holdings ranks better than 81.88% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). MeiraGTx Holdings's share price for the quarter that ended in Mar. 2026 was €7.2. MeiraGTx Holdings's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 81.45 Mil. Therefore, MeiraGTx Holdings's market cap for the quarter that ended in Mar. 2026 was €586.41 Mil.

MeiraGTx Holdings's quarterly market cap declined from Sep. 2025 (€559.34 Mil) to Dec. 2025 (€531.34 Mil) but then increased from Dec. 2025 (€531.34 Mil) to Mar. 2026 (€586.41 Mil).

MeiraGTx Holdings's annual market cap increased from Dec. 2023 (€403.87 Mil) to Dec. 2024 (€458.62 Mil) and increased from Dec. 2024 (€458.62 Mil) to Dec. 2025 (€531.34 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. MeiraGTx Holdings's Enterprise Value for Today is €997.95 Mil.


MeiraGTx Holdings  (FRA:328) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


MeiraGTx Holdings Market Cap Related Terms


MeiraGTx Holdings Market Cap Historical Data

* Premium members only.

The historical data trend for MeiraGTx Holdings's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeiraGTx Holdings Market Cap Chart

MeiraGTx Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 917.71 283.59 403.87 458.62 531.34

MeiraGTx Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 528.13 446.48 559.34 531.34 586.41

FRA:328 vs DRTS, LXRX, CGEM: Market Cap Comparison

For the Biotechnology subindustry, MeiraGTx Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MeiraGTx Holdings Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MeiraGTx Holdings's Market Cap distribution charts can be found below:

* The bar in red indicates where MeiraGTx Holdings's Market Cap falls into.


FRA:328
55GF Score
MeiraGTx Holdings PLC FRA:328
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MeiraGTx Holdings Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

MeiraGTx Holdings's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as

Market Cap (A: Dec. 2025 )=Share Price (A: Dec. 2025 )*Shares Outstanding (EOP) (A: Dec. 2025 )
=€6.55*81.121
=€531.34

MeiraGTx Holdings's Market Cap for the quarter that ended in Mar. 2026 is calculated as

Market Cap (Q: Mar. 2026 )=Share Price (Q: Mar. 2026 )*Shares Outstanding (EOP) (Q: Mar. 2026 )
=€7.2*81.446
=€586.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of €983.87 Mil mean?
MeiraGTx Holdings (FRA:328) has a Market Cap of €983.87 Mil as of Jun. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MeiraGTx Holdings and its competitors. According to the industry distribution chart, MeiraGTx Holdings ranks #259 out of 1429 companies in the Biotechnology industry, placing it in the top 18.1%.
Is MeiraGTx Holdings' Market Cap too high?
MeiraGTx Holdings' current Market Cap is €983.87 Mil. Based on the distribution chart, MeiraGTx Holdings ranks #259 out of 1429 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, MeiraGTx Holdings has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' Market Cap compare to DRTS and LXRX?
According to the Biotechnology industry distribution chart, MeiraGTx Holdings ranks #259 out of 1429 companies for Market Cap. This places MeiraGTx Holdings in the top 18% of its industry — outperforming the majority of peers. The industry median Market Cap is 112.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 112.70, based on 1,429 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on MeiraGTx Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 112.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeiraGTx Holdings's current Market Cap is €983.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €19.70, compared to a current price of €10.00 — trading 49.2% below its estimated fair value. The current Market Cap is €983.87 Mil. MeiraGTx Holdings' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current Market Cap is €983.87 Mil as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?

Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued. The current stock price of €10.00 is trading 49.2% below its estimated GF Value™ of €19.70. GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.

Key valuation signals for FRA:328:

  • Market Cap: €983.87 Mil
  • GF Value™: €19.70 vs. price of €10.00 (49.2% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MeiraGTx Holdings Business Description

Other Exchanges MGTX:USA328:Germany
Address 655 Third Avenue, Suite 1115, New York, NY, USA, 10017
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
55GF Score

Get the complete analysis for FRA:328

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.00
Price
€19.70
GF Value